Eikon Therapeutics (EIKN) logo

Eikon Therapeutics (EIKN) stock

Medicines , market cap $446M

$5.54
-23.69%

As of Monday's close · Live for Pro members at the open

Quality Score
0
Below Average
In its industry
#128of 291

EIKN's Quality Score fell 1 point on Mon, Oct 26, to 0. Left its tight band (2 chart checks stopped).

New listing, trading since Feb 5, 2026. 182 trading days so far, so 1 of the 14 chart checks waits for more history.

Follow EIKN's trial news. Pro members can get an alert when Eikon Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when EIKN files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“…preclinical studies now tracking ahead of schedule, expected to enable IND submission by the end of 2026”Filing with regulators · SEC filing · Aug 14

Why is EIKN down?

Down 24% on Oct 26.

“Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress.”

Its release that day said

Sources: Price history, Oct 26, 2026; Company release (8-K), Oct 26, 2026

−2Volatility moves 13.8% a day with no profit or positive free cash flow over four quarters on file

2 more reasons why EIKN fell on Oct 26, from its filings, with the timeline and its peers, for Pro members.

Key facts on EIKN

Key facts on EIKN
Holding it backMoves 13.8% a day with no profit behind it
Latest filing8-K, Oct 26 Issued a release: "Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress"

EIKN in the news

What's next

Fri Feb 5: One year since its IPOListed Feb 5, 2026 at $18.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

EIKN catalysts

Coming up

After its last 3 reports it closed +7.2% on average, higher 2 of 3 times.

3 more coming up and 2 past catalysts since 2026, with sizes and sources, for Pro members.Get in free →

What's next for EIKN, and how long its cash lasts

Next step the company has named

End of 2026“…of emerging resistant variants EIK1006 declared clinical candidate in November 2025; preclinical studies now tracking ahead of schedule, expected to enable IND submission by the end of 2026”Filing with regulators · SEC filing · Aug 14

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program
EIK1006
Another trial
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.Phase 2/3 · Recruiting · 740 people · main data estimated Dec 2035 · NCT06697301

5 more trials, 1 with data due this year, 3 more milestones and 10 filings, for Pro members.

Cash runway Jun 30 balance sheet

$531M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into the second half of 2027” (8-K, Aug 13).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Kenneth C Frazier bought 111,111 shares on Feb 4. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Roger Perlmutter’s 3 filings and quotes.

Get an alert when EIKN files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on EIKN and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

EIKN has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on EIKN, and all 14 on every stock.Get in free →

EIKN RSI today: 29.5, below its 50-day average

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

The deep dive on EIKN

5 more findings on EIKN, each with its source, for Pro membersGet in free →

How EIKN ranks in Biotech

EIKN is #128 of 291 by Quality Score.

How EIKN ranks in Biotech
128Eikon Therapeutics (EIKN) logoEIKNEikon Therapeutics0

More in Biotech

When does EIKN report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 17 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What EIKN reported on Aug 13, 2026

The quarter

The figures are not read from the release yet.

“The decrease was primarily due to the impairment in the year-ago period of $10.7 million of property and equipment and $10.3 million of operating lease right-of-use assets relating to properties in Hayward, California that Eikon vacated in April 2025 when the Company moved into its current corporate headquarters in Millbrae, California.”

The filing on EDGAR

Where the sales came from

EIKN's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value
$446M
today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on EIKN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →
ReportedGapReaction5
sessions
Aug 13, 2026After close+3.8%+7.0%+4.1%
May 11, 2026After close+6.1%+15.9%+18.1%
Mar 30, 2026Before open-0.1%-1.3%-3.8%

EIKN closed higher after 2 of its last 3 reports.

EIKN share count over time

Shares: 19.0 times the count a year ago (to Jun 30).

Shares of EIKN outstanding, as filed
Shares
outstanding
As
of
54.2MAug 3, 2026
54.1MMay 1, 2026
Offerings, shelves, and splits of EIKN, from its filings
From its
filings
Filed
Raised $381.2M in a sale of shares, about 85% of its market valueFeb 5, 2026
Registered shares for sale (S-1)Jan 9, 2026

Who is trading EIKN

EIKN insider trades

One insider bought $1M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest:

BuyColumn Group IV GP, LP$1M10% ownerat $11.56 on Sep 3, filed Sep 8

EIKN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold EIKN?

In ETFs: EIKN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Eikon Therapeutics

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

384 employeesMillbrae, CAeikontx.com

Listed on Nasdaq on Feb 5, 2026, and is 69% below its $18 offer price now. Its IPO filing and first days

EIKN's score card

Eikon Therapeutics (EIKN): Quality Score 0, Below Average, #128 of 291 in Biotech, with its price, on Breakaway
The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

  • What would turn EIKN's score around: 4 things
  • 4 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawaySep 8Column Group IV GP, LP bought EIKN$1M at $11.56, filed Sep 8

Alerts are optional.

See EIKN's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: EIKN's Quality Score is 0 (Below Average), #128 of 291 in Biotech. Insiders bought $1M in the last 6 months (Form 4).

Is EIKN a good stock to buy? What its Quality Score says

EIKN scores 0 today, which Breakaway calls Below Average. It is #128 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 24% on Oct 26. Shares: 19.0 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is EIKN's Quality Score?

EIKN scores 0 today, which Breakaway calls Below Average (0 to 5). That is #128 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind EIKN's 0.

Are insiders buying EIKN?

One insider bought $1M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest is Column Group IV GP, LP, 10% owner, who bought $1M on Sep 3.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

What's next for Eikon Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs; recorded live since Sep 9 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.